Qualitative assessment reveals GPs' views on the diagnostic process and implementation challenges for AD blood biomarkers.
BACKGROUND Alzheimer's disease (AD) blood biomarkers could improve the diagnostic process for patients with cognitive complaints presenting to primary care. We investigated general practitioners’ (GPs’) perspectives on facilitating and hindering factors associated with the use and implementation of AD blood biomarkers. METHOD In this qualitative, semi‐structured interview study, we used purposive sampling to recruit a heterogeneous group of 18 Dutch GPs. Qualitative data analysis of interview transcripts was based on the Theoretical Domains Framework. RESULTS GPs believed that AD blood biomarkers could have both positive and negative consequences. Mentioned positive consequences included facilitating an accessible diagnostic process, clarity about the etiology, and life planning. Mentioned negative consequences were imposing a psychological burden on patients and possible AD over‐ or underdiagnosis. CONCLUSION While AD blood biomarkers may have potential benefits according to GPs, additional evidence, definition of context of use and logistics, and adoption of guidelines are needed for eventual implementation. Highlights GPs experience a knowledge gap regarding AD and AD blood biomarkers AD blood biomarkers could inform GPs, enabling decision‐making in primary care GPs perceive various harms and benefits associated with the use of AD biomarkers Information, education and guidelines are key factors for successful implementation
No takes yet. Share an insight, caveat, or question.
Claessen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: